Figure 4.
Mouse tumor exome sequencing in IL-6+/-/Pax5+/- B-ALL. (a) Whole-exome sequencing analysis of tumor and control samples. Tumor-specific somatic mutations were determined by mutect and varscan analysis. The number of somatic cancer genes was calculated by using the cancer gene consensus list. The percentage of leukemic cells for each mouse was: 98% (U971) from total BM, 90% (U572) from total BM, 90% (L370) from total BM and 20% (L371) from total LN. (b) Genomic comparison between mutations driving native B-ALL as a result of natural infection exposure of IL-6+/+/Pax5+/- (previously described in Martin-Lorenzo, A. et al.9) (orange) and IL-6+/-/Pax5+/- mice (violet), respectively, showed that similar second hits were affected by recurrent mutations.